Illumina

Bahrain, First in the Middle East to Acquire Latest Machine used for Human Genome Sequencing

Retrieved on: 
Tuesday, November 28, 2023
Ministry, Research, Ministry of Health (Bahrain), Al-Zahrawi, Emerging market, Genomics, Supreme Council, GCC, Harvard University, Medical device, Health, Illumina, Kingdom

MANAMA, Bahrain, Nov. 28, 2023 /PRNewswire/ -- The Ministry of Health in the Kingdom of Bahrain has become the first in the Middle East to acquire and inaugurate the use of the cutting-edge NovaSeqTM X Plus machine for human genome sequencing purposes.

Key Points: 
  • MANAMA, Bahrain, Nov. 28, 2023 /PRNewswire/ -- The Ministry of Health in the Kingdom of Bahrain has become the first in the Middle East to acquire and inaugurate the use of the cutting-edge NovaSeqTM X Plus machine for human genome sequencing purposes.
  • The move is part of the Kingdom's commitment to continue developing therapeutic and diagnostic services in line with latest global medical advancements, benefiting the health of all.
  • The Chairman of the Supreme Council of Health, Lt. General Dr. Shaikh Mohammed bin Abdulla Al Khalifa, highlighted the ongoing efforts within the National Genome Project, which aims to utilize gene sequencing in adopting effective national health policies and therapeutic and preventative management plans.
  • A national delegation of specialists from the National Genome Centre was sent to Harvard University in the United States to undergo specialized training, including the latest methods of genome sequencing, biological data classification, clinical analysis, scientific data analysis, and genetic data management.

Bahrain, First in the Middle East to Acquire Latest Machine used for Human Genome Sequencing

Retrieved on: 
Tuesday, November 28, 2023
Ministry, Research, Ministry of Health (Bahrain), Al-Zahrawi, Emerging market, Genomics, Supreme Council, GCC, Harvard University, Medical device, Health, Illumina, Kingdom

MANAMA, Bahrain, Nov. 28, 2023 /PRNewswire/ -- The Ministry of Health in the Kingdom of Bahrain has become the first in the Middle East to acquire and inaugurate the use of the cutting-edge NovaSeqTM X Plus machine for human genome sequencing purposes.

Key Points: 
  • MANAMA, Bahrain, Nov. 28, 2023 /PRNewswire/ -- The Ministry of Health in the Kingdom of Bahrain has become the first in the Middle East to acquire and inaugurate the use of the cutting-edge NovaSeqTM X Plus machine for human genome sequencing purposes.
  • The move is part of the Kingdom's commitment to continue developing therapeutic and diagnostic services in line with latest global medical advancements, benefiting the health of all.
  • The Chairman of the Supreme Council of Health, Lt. General Dr. Shaikh Mohammed bin Abdulla Al Khalifa, highlighted the ongoing efforts within the National Genome Project, which aims to utilize gene sequencing in adopting effective national health policies and therapeutic and preventative management plans.
  • A national delegation of specialists from the National Genome Centre was sent to Harvard University in the United States to undergo specialized training, including the latest methods of genome sequencing, biological data classification, clinical analysis, scientific data analysis, and genetic data management.

Beauvince Unveils The Iconics, an Exquisite High Jewelry Collection for the Holiday Season

Retrieved on: 
Tuesday, November 21, 2023
Diamond, Emerald, Elation Freedom Iconic Collection, Collection, Platinum, Beauty, Gold, Magic, White Diamonds, CTS, Wizard, Freedom, Growth, Dream, Illumina, Ruby, Gemstone, Jewellery, Iconics

NEW YORK, Nov. 21, 2023 /PRNewswire-PRWeb/ -- Beauvince, renowned international purveyor of high-end jewelry, is delighted to present its new collection, The Iconics, just in time for the holiday season. For 2023, the brand takes the holiday spirit to new heights by celebrating a dazzling trend: the harmonious fusion of yellow diamonds set in yellow gold, combined with white diamonds set in platinum. The Iconics have an exquisite blend of colors and brilliance that create a unique and unforgettable statement, perfect for celebrating the season's magic.

Key Points: 
  • We love diamonds and this season we wanted to explore the interplay of the warmer yellows with the classic white.
  • Bringing the extraordinary to clientele in time for the holiday season, Beauvince seamlessly merges the brilliance of yellow diamonds with the classic elegance of white diamonds.
  • We love diamonds and this season we wanted to explore the interplay of the warmer yellows with the classic white.
  • To learn more about The Iconics Collection and Beauvince Jewelry, visit beauvince.com, call 646-775-8724 or email [email protected] .

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

Retrieved on: 
Friday, November 17, 2023
Sale, 10x Genomics, NanoString Technologies, Monsanto legal cases, UPC, Prognosis marker, Genomics, District court, Patent, RNA, Generic drug, Television, Illumina

PLEASANTON, Calif., Nov. 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of 10x Genomics in the patent infringement suit 10x filed against the GeoMx products sold by NanoString Technologies, Inc. (Nasdaq: NSTG). In awarding over $31 million in damages, the jury found that NanoString's GeoMx Digital Spatial Profiler and associated instruments, reagents and services for RNA and protein detection willfully infringe all seven asserted patents owned by Prognosys and exclusively licensed to 10x Genomics.

Key Points: 
  • GeoMx Decision is Third Ruling Against NanoString, Showing Serial Infringement of 10x Patents
    PLEASANTON, Calif., Nov. 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of 10x Genomics in the patent infringement suit 10x filed against the GeoMx products sold by NanoString Technologies, Inc. (Nasdaq: NSTG ).
  • "In the last six months, three separate courts have found that both NanoString's CosMx and GeoMx products infringe nine separate 10x patents," said Eric Whitaker, Chief Legal Officer at 10x Genomics.
  • "At some point, NanoString must drop the charade that it is 'confident' it does not infringe the 10x patents and the patents are invalid.
  • This ruling is the third time that NanoString has been found to infringe 10x patents in the past six months.

Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries

Retrieved on: 
Monday, November 13, 2023
World Health Organization, Pandemic, Tuberculosis, SAN, DNA, Organization, Disease, WHO, Risk, Genomics, Molecular epidemiology, Data analysis, Whole genome sequencing, Illumina, Inc., Drug resistance, Clinical epidemiology, SARS-COV-2, Virus, GISAID, AIDS, Communication, Moeder, SARS-CoV-2, Face, Public, Influenza-like illness, Vaccine, Renewable energy, Malaria, Developing country, Illumina

SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs). The program, developed with guidance from customers, funders, and market facilitators including the nonprofit FIND, will provide reduced pricing structures for eligible sequencing products from Illumina to qualified global health funding entities and address key international logistics and supply chain challenges.

Key Points: 
  • SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs).
  • "We know that enabling countries to perform pathogen sequencing locally strengthens health systems, enables better preparedness, and empowers countries to manage their priority health threats," said Vanessa Moeder, head of Global Health at Illumina.
  • In the Illumina global team's experience, Moeder says, the countries or regions whose public health preparedness would most benefit from genomics often lack the resources to sustainably implement it.
  • The equitable access program developed and operationalized by Illumina will allow many low- and middle-income nations to participate in the future of genomics across public health and preparedness."

Veracyte Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, Radiation therapy, IVD, GAAP, Acquisition, Prostate cancer, JCO, Society, Prostate, Growth, Webcast, Abstract, American Society for Radiation Oncology, Cancer, ASTRO, Table, Patient, GM, GRID, Pharmaceutical industry, Video game, Medical imaging, Illumina

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2023.
  • Total revenue for the third quarter of 2023 was $90.1 million, an increase of 19% compared to $75.6 million reported in the third quarter of 2022.
  • Total gross margin for the third quarter of 2023, including the amortization of acquired intangible assets, was 64%, compared to 59% in the third quarter of 2022.
  • Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update.

Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Medical Devices, Health, Pharmaceutical, Oncology, Laboratory, Real-time, IVD, Physician, Illumina, Inc., CLIA, NGS, Cancer, Hospital, Smoker, Patient, Diagnosis, Pharmaceutical industry, Medical imaging, Illumina

(Nasdaq: VCYT) today announced that it has entered into a multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx next-generation sequencing (NGS) instrument.

Key Points: 
  • (Nasdaq: VCYT) today announced that it has entered into a multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx next-generation sequencing (NGS) instrument.
  • The agreement is part of Veracyte’s expanded, multi-platform IVD approach, which will also include qPCR and is designed to accelerate the company’s ability to make its tests available to more patients globally.
  • The first tests that Veracyte plans to develop for the Illumina NextSeq 550Dx instrument are its Prosigna Breast Cancer Assay and Percepta Nasal Swab test.
  • Prosigna is already commercially available as an IVD test that helps inform treatment decisions for patients with early-stage breast cancer.

King Faisal Specialist Hospital & Research Centre Successfully Concludes its Role as a Strategic Healthcare Partner at Global Health Exhibition 2023

Retrieved on: 
Monday, November 6, 2023
Space research, Arm, RC, Radiopharmaceutical, STC, SABIC, Health, Research, Medical tourism, KFSH, Mou Zongsan, Partnership, Pleasure, Corporate communication, Health care, Microsoft, Johnson & Johnson, Patient, T cell, Longevity, Pharmaceutical industry, Illumina, Kingdom

RIYADH, Saudi Arabia, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The Global Health Exhibition, held from October 29 to October 31, 2023, proved an outstanding success for the King Faisal Specialist Hospital & Research Centre (KFSH&RC).

Key Points: 
  • RIYADH, Saudi Arabia, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The Global Health Exhibition, held from October 29 to October 31, 2023, proved an outstanding success for the King Faisal Specialist Hospital & Research Centre (KFSH&RC).
  • “KFSH&RC's transformative journey into a non-profit institution, primarily focusing on serving patients from the Gulf region, began in 2021.
  • The Global Health Exhibition has been a remarkable platform to explore new opportunities that will further bolster the healthcare landscape in the Kingdom and beyond."
  • The hospital also received the prestigious "Best Public Services Call Centre of The Year – Critical" award at the Annual Middle East Call Centre 2023 Awards.

Myriad Genetics Appoints Sam Raha as Chief Operating Officer

Retrieved on: 
Wednesday, November 1, 2023
Genetic testing, Myriad Genetics, Cell biology, Genetics, MBA, Global marketing, Association for Molecular Pathology v. Myriad Genetics, Inc., SALT, MYGN, Growth, Santa Clara University, Medicine, University, Berkeley, Management, Illumina, Agilent Technologies

SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December 11, 2023.

Key Points: 
  • SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December 11, 2023.
  • Raha adds more than 25 years of general management, commercial, and operations experience, deeply rooted in life sciences and molecular diagnostics, to the team at Myriad Genetics.
  • In his role as COO, he will be responsible for driving the company’s lab operations, customer service initiatives, and product development innovations.
  • “Sam is an accomplished leader who understands how to build teams and drive a patient-centric culture, with a proven ability to define, execute and deliver profitable growth for companies within the diagnostics space,” said Paul Diaz, President and CEO, Myriad Genetics.

Illumina: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Tuesday, October 31, 2023
Illumina, Inc., Illumina

LOS ANGELES, Oct. 31, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) investors that the firm has initiated an investigation into possible securities violations and may file a class action on behalf of investors. Illumina investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, Oct. 31, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) investors that the firm has initiated an investigation into possible securities violations and may file a class action on behalf of investors.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The company is being investigated for potential breaches of fiduciary duty on the part of its directors and management.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.